Small pharmaceutical company plans on reviving failed cholesterol medication
DalCor Pharmaceuticals has raised $150 million to launch a clinical trial involving a cholesterol drug (dalcetrapib) that did not prevent MI and strokes in a previous phase 3 trial, the Wall Street Journal reports.
Roche Holding AG discontinued manufacturing dalcetrapib following the failed study. DalCor plans on enrolling patients with a favorable genetic profile.
For more, check out the link below:
Executive Editor
Tim Casey joined TriMed Media Group in 2015 as Executive Editor. For the previous four years, he worked as an editor and writer for HMP Communications, primarily focused on covering managed care issues and reporting from medical and health care conferences. He was also a staff reporter at the Sacramento Bee for more than four years covering professional, college and high school sports. He earned his undergraduate degree in psychology from the University of Notre Dame and his MBA degree from Georgetown University.